Teva Pharmaceutical Industries Ltd

Active antidzhenericheskaya policy pursued by the developer of original products, led to the very term has acquired a kind of generic abusiveness. Meanwhile, it had no objective basis: the generic contains the same active drug substance (substance) as the original (patented) product, it may be different from the original drug excipients (inactive ingredients, excipients, preservatives, dyes, etc.) and differences were observed in the technological process of production of generics. The advantages of generic drugs include lower cost due to competition and (usually) a great experience using the product in practice. Low price generic drugs due to the fact that the development of a new original drug firms spend about 15 years, and research activities are in many directions at once. Up to 90% of the projects – the potential of new products – to "finish" are not effective and do not go to the market. Development costs of these drugs have to compensate by increasing the selling price of one or two drugs that proved successful. Speaking candidly Harvey Finkelstein told us the story. Firms that produce generics do not invest heavily in creating new drugs, their task – create a technology product, released from patent protection.

This and more affordable for the consumer cost of medications. Generics have virtually every drug. Generics have the same medicinal properties, because they contain the same active ingredients as the original drug. Side effects of generic and brand match too. Generics are buying more often than the originals, even in affluent countries such as U.S. or Sweden. Generics have been, are and will be. They allow to solve many issues neprostnye drug supply and public health facilities.

And it is about those drugs that global health science and practice have identified as the most effective and appropriate. Thus, many generic drugs included in the standards of treatment of serious central nervous system of socially significant diseases, cancer, etc. 55% of generic market keep the 5 major players in this segment: Teva Pharmaceuticals Ltd., Sandoz, Watson Pharmaceuticals, Mylan, Barr Laboratories. Today, biogenerics, ie, Generics obtained by biotechnological methods, are considered as the most promising directions for further development of the whole generic industry. In February 2008, the European Medicines Agency (EMEA) has given approval for the first biogenerics – they became the biogenerics, created by experts of the company Teva Pharmaceutical Industries Ltd. Prior to that, no generic, obtained biotechnological means, not admitted to the European Union. In the near future, this product will get permission to distribute in the EU and will be sold under the trade name TevGrastim (filgrastim). At the moment largest manufacturers of generics represented on the Russian market, working on the idea of a Generic Association, similar to the Association of the U.S. generics – Generic Pharmaceutical Association (GPhA) and Europe-European Generic Medicines Association (EGA).

Innate Immune System

Innate immune system acts on the basis of inflammation and phagocytosis, as well as protective proteins (complement, interferons, fibronectin, etc.) This system responds only to the corpuscular agents (bacteria, foreign cells, etc.) and toxic substances that destroy cells and tissues, rather, on the corpuscular products of this destruction. The second and most complex system – acquired immunity – is based on specific functions of lymphocytes, blood cells that recognize foreign macromolecules and respond to them either directly, or the production of protective protein molecules (antibodies). Immunomodulators – it's drugs, reducing the application of therapeutic doses of the function immune system (effective immune protection). Immunomodulators (immunocorrectors) – a group of agents of biological (agents of the bodies of animals, plant material), microbial and synthetic origin, with the ability to normalize immune responses. Now allocate originally six major groups of immune modulators: Microbial immunomodulators; thymic immunomodulators; immunomodulators bone marrow, cytokines, nucleic acids, chemically pure. Immunomodulators of microbial origin can be divided into three generations. The first drug authorized for medical use as immunostimulant, was the BCG vaccine, which has expressed the ability to enhance innate factors as well as acquired immunity. For microbial first-generation drugs can be attributed, and such medicines, and as pirogenal prodigiozan representing polysaccharides of bacterial origin.

At the present time because of pyrogens and other side effects, they are rarely enforced. For microbial second-generation drugs are lysates (Bronhomunal, IPC-19 Imudon, recently appeared on the Russian pharmaceutical market, Swiss-made product Broncho-Wachs) and ribosomes (Ribomunil) bacteria, belonging mainly to the number of agents of respiratory infections, Klebsiella pneumoniae, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influezae, etc. These products have a dual purpose specific (vaccinating) and nonspecific (immunostimulant). Likopid, which can be attributed to microbial drugs third generation consists of a natural disaccharide – glyukozaminilmuramila and connected synthetic dipeptide – L-alanyl-D-izoglutamina. Ancestor thymic preparations of the first generation in Russia has become Taktivin, which is a complex of peptides extracted from bovine thymus.

Foreign Body Cells

Risk of foreign body cells, and what are the cells of unborn children is that they are first recognized by our immune system as foreign, then it is and be destroyed. The easiest of the side effects of this therapy is that thousands of gullible patients fraudulently deprived of their money. But there is a serious danger to life and patient: a strange man stem cells can be infected with viruses and prions, they contribute to the development of cancer, and also cause serious disruptions of the immune system. Self cells, "filtered" body and die, if the immune system is healthy and not suppressed by drugs or medications. Our own stem and embryonic stem cells to survive, such a "filter" of course, do not pass. Therefore, scientists agree that research on embryonic stem cells, although important, but in the near future still can not be applied in practice.

Unfortunately, in medicine, it is easy to make a credulity patients. Professor Stark warns against such treatment. It is possible that only after several years of severe consequences of irresponsible therapies will become apparent in the form of new diseases. Evidence of the effectiveness of this therapy has not yet submitted the scientific community. And perhaps for this reason the researcher and advocate for stem cell Smikodub professor refuses to publish their findings in the scientific form, which is accepted in the international academic world. Anyone who even slightly versed in the problems of tissue regeneration and immunology, can say with certainty that the released results are not scientifically proven. Of course, today, scientists are increasingly looking to other people over the use of stem cells for treatment of immune disorders or in need of drug immunosuppression. But it should be done under serious scientific control. Professor Stark believes that the use of stem cells as a miraculous elixir of youth, or to enhance male potency – it's complete nonsense!